OctoPlus signed agreement with leading pharmaceutical company
Published : Wednesday, January 11, 2012
OctoPlus N.V. announced that it has signed a feasibility agreement with a leading US-based pharmaceutical company, aimed at developing a controlled release formulation of the client’s therapeutic compound for local delivery into joints.
This contract covers initial activities in developing a controlled release formulation of an undisclosed compound using our proprietary drug delivery technology PolyActive®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.
top of page|- print|
- sitemap|
- login|
- links|
- mailform|
- map
- for more information call us: +31 (0)71 524 75 55 or email us: info@leidenbiosciencepark.nl

